Articles By Jack Cush, MD
ACR 2019 – Best of the Plenary Sessions
The ACR Plenary Sessions featured some of the best research presented on Sunday, Monday, and Tuesday in Atlanta. Here are my seven notable highlights from the Plenaries.
Read Article
ACR 2019 - Report from Day One (Sunday)
Sunday was the first full day of scientific sessions at the 2019 ACR/ARP meeting in Atlanta. Yesterday we shared our initial news articles, videos and more with you. Following is my roundup of day one. Delays in Diagnosis
Read Article
RheumNow Podcast – ACR 2019 Round Up (11.15.19)
Dr. Jack Cush presents his favorite abstracts and presentations from Rheumatology Round Up and ACR 2019.
Read Article
RheumNow Podcast – Better Ways to Treat Gout (11.8.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
T2T Lowers Mortality in Gout
A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.
Read Article
Most Psoriatics Go on Biologics
A cohort study of 97 patients with psoriatic arthritis (PsA) examined the prescribing practices in PsA, and found biologics are commonly initiated as the primary mode of therapy in outpatients with PsA. However, treatment modifications can be made regarding patients who are managed with apremilast alone.
Read Article
New EMA Warnings for Tofacitinib in Patients at Risk for Clots
The European Medicines Agency safety committee (PRAC) has concluded that Xeljanz (tofacitinib - TOFA) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk for venous thromboembolic events. The PRAC is recommending that TOFA should be used with caution in patients at high risk of blood clots (VTE), regardless of dose used.
Read Article
Mallinckrodt Receives SEC Subpoena
Reuters reports that Mallinckrodt Plc has received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).
Read Article
Physical Activity Lowers Fracture Risk in Post-Menopausal Women
An analysis from the Women’s Health Initiative study shows that postmenopausal women who participate in vigorous physical activity have a statistically lower risk of total and site-specific fractures
Read Article
EXCEED Study: Cosentyx Equals Humira in Psoriatic Arthritis
Novartis has announced the results of the EXCEED trial that pitted its IL-17 inhibitor, Cosentyx (secukinumab - SEC) against Humira (adalimumab - ADA) in patients with active psoriatic arthritis. The trial demonstrated that SEC was not non-inferior to ADA, but failed to meet its primary endpoint of superiority over ADA as far as drug efficacy.
Read Article